Spyre Therapeutics, Inc. (SYRE) Misses Q1 EPS by 7c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q1 EPS of ($0.74), $0.07 worse than the analyst estimate of ($0.67).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• Putin Said To Plan Ukraine Escalation, Seeing Talks Fruitless - Bloomberg
• Dycom Industries (DY) Tops Q2 EPS by 59c, Beats on Revenue
• LightInTheBox Holding (LITB) Reports Q2 EPS of $0.01